• Search
  • Advanced Search
Clin Mol Hepatol > Accepted Articles
Editorial
Metformin and Statins and their role in reducing Hepatocellular Carcinoma Risk: Randomized trials are needed
Paul Y. Kwo
Division of Gastroenterology and Hepatology, Stanford University Medical School, Stanford, California, USA
Correspondence :  Paul Y. Kwo ,
Tel: 6507237040, Email: pkwo@stanford.edu
Received: June 4, 2024   Accepted: June 6, 2024
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 264 View
  • 22 Download
Related articles

Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy2024 July;30(3)

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective2023 April;29(2)

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?2022 July;28(3)

Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers2019 September;25(3)

The Factors Related to the Prognosis of Solitary Hepatocellular Carcinoma after Radiofrequency Ablation2005 December;11(4)

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 380
TOTAL : 1931483
Close layer